EndoChoice IPO raises $95M; Boston Scientific launches tiny, high-capacity neurostim pain implant;

@FierceMedDev: Exact Sciences joins forces with MD Anderson for lung cancer Dx development. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: Journalists who were jailed by the feds call for federal shield law | National Press Club. More | Follow @VarunSaxena2

@EmilyWFierce: OPKO scoops up Bio-Reference Laboratories for $1.47B. News | Follow @EmilyWFierce

> EndoChoice ($GI) priced its IPO at $15; that's at the bottom of its proposed price range. The better-view-endoscopy player sold 6.4 million shares, a bit more than the proposed 6.25 million. That raised $95 million for the company. More

> Boston Scientific ($BSX) had a European launch for its Precision Novi Spinal Cord Stimulator (SCS) System, which it noted is the smallest, marketed high-capacity primary cell device. More

> Philips' ($PHG) Respironics business launched its Alice NightOne at-home sleep testing system (HST). It's designed to enable at-home sleep disorder diagnostics that are faster, easier and more reliable than laboratory sleep testing. More

> National Institutes of Health (NIH) researchers conducted a study of the genomes of almost 1,000 putatively healthy individuals. Of these, about 100 had genomic variants that would predict them to have a rare disease. About half of them did indeed have the disease. This caused them to raise their estimate to 3% of the U.S. population having a genetic disease, compared with previous estimate of less than 0.02%. More

Biotech News

@FierceBiotech: FDA says Sanofi and Regeneron's cardio contender looks approvable. But for whom? More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Vertex beefs up its cystic fibrosis pipeline with $1.2B Parion R&D pact. Article | Follow @JohnCFierce

@DamianFierce: Next week's PCSK9 adcomms are at the "Hilton Washington DC/Gaithersburg," which is like saying "Marriott U.S./Greenland." | Follow @DamianFierce

> Abivax tees up a $49M IPO to get its hep B shot into Phase III. Story

> NIH slams the brakes on drug production after contamination scare. Report

Pharma News

@FiercePharma: FDA launches safety investigation of controversial raw foods for pets. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: FDA warning letter says Czech company shipped bacteria contaminated APIs to the U.S. More | Follow @EricPFierce

@CarlyHFierce: AbbVie, J&J gallop toward first-line Imbruvica sales with new survival data. FiercePharma report | Follow @CarlyHFierce

> AstraZeneca takes its emerging markets push to Algeria with $125M expansion. Story

> NICE sings a different tune for Bayer's prostate cancer drug Xofigo. Report